WO2006090759A1 - ソリフェナシン含有医薬 - Google Patents
ソリフェナシン含有医薬 Download PDFInfo
- Publication number
- WO2006090759A1 WO2006090759A1 PCT/JP2006/303226 JP2006303226W WO2006090759A1 WO 2006090759 A1 WO2006090759 A1 WO 2006090759A1 JP 2006303226 W JP2006303226 W JP 2006303226W WO 2006090759 A1 WO2006090759 A1 WO 2006090759A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solifenacin
- urinary
- bladder
- urgency
- solifenacin succinate
- Prior art date
Links
- 229960003855 solifenacin Drugs 0.000 title claims abstract description 45
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 title claims abstract description 45
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims abstract description 70
- 206010029279 Neurogenic bladder Diseases 0.000 claims abstract description 70
- 206010046543 Urinary incontinence Diseases 0.000 claims abstract description 61
- 206010027566 Micturition urgency Diseases 0.000 claims abstract description 50
- FBOUYBDGKBSUES-KEKNWZKVSA-N 1-azabicyclo[2.2.2]octan-3-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(OC2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-KEKNWZKVSA-N 0.000 claims abstract description 48
- 229960001368 solifenacin succinate Drugs 0.000 claims abstract description 48
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 230000027939 micturition Effects 0.000 claims description 73
- 239000003814 drug Substances 0.000 claims description 50
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 30
- 210000002700 urine Anatomy 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 206010036018 Pollakiuria Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 10
- 206010041591 Spinal osteoarthritis Diseases 0.000 abstract description 9
- 208000020431 spinal cord injury Diseases 0.000 abstract description 7
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 6
- 208000005801 spondylosis Diseases 0.000 abstract description 6
- 208000029028 brain injury Diseases 0.000 abstract description 4
- 210000000278 spinal cord Anatomy 0.000 abstract description 4
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 abstract description 3
- 208000031481 Pathologic Constriction Diseases 0.000 abstract description 3
- 206010041549 Spinal cord compression Diseases 0.000 abstract description 3
- 208000007103 Spondylolisthesis Diseases 0.000 abstract description 3
- 210000004556 brain Anatomy 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 210000001428 peripheral nervous system Anatomy 0.000 abstract description 3
- 230000036262 stenosis Effects 0.000 abstract description 3
- 208000037804 stenosis Diseases 0.000 abstract description 3
- 230000008733 trauma Effects 0.000 abstract description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 230000004770 neurodegeneration Effects 0.000 abstract description 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 2
- 206010059150 Cerebrosclerosis Diseases 0.000 abstract 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 201000005671 spondyloarthropathy Diseases 0.000 abstract 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 37
- 210000003932 urinary bladder Anatomy 0.000 description 22
- 229940079593 drug Drugs 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 230000006872 improvement Effects 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 17
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 10
- 206010008118 cerebral infarction Diseases 0.000 description 10
- 239000003149 muscarinic antagonist Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000022934 urinary frequency Diseases 0.000 description 8
- 230000036318 urination frequency Effects 0.000 description 8
- 238000001647 drug administration Methods 0.000 description 7
- 206010021639 Incontinence Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- HWMFFWCDLWDYGX-UHFFFAOYSA-N n-(4-aminophenyl)furan-2-carboxamide Chemical compound C1=CC(N)=CC=C1NC(=O)C1=CC=CO1 HWMFFWCDLWDYGX-UHFFFAOYSA-N 0.000 description 6
- -1 oxibutun Chemical compound 0.000 description 6
- 229960001187 propiverine hydrochloride Drugs 0.000 description 6
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 5
- 235000017663 capsaicin Nutrition 0.000 description 5
- 229960002504 capsaicin Drugs 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000020629 overactive bladder Diseases 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
- 208000005615 Interstitial Cystitis Diseases 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229960004045 tolterodine Drugs 0.000 description 4
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 4
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 208000036319 cervical spondylosis Diseases 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000009911 Urinary Calculi Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001022 anti-muscarinic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000036453 micturition reflex Effects 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960003510 propiverine Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 229940016173 solifenacin succinate 5 mg Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 230000003202 urodynamic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010052346 Brain contusion Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960002677 darifenacin Drugs 0.000 description 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MIOUTPXNKVBIFR-UHFFFAOYSA-J dicalcium 2-hydroxyacetate Chemical compound C(CO)(=O)[O-].[Ca+2].[Ca+2].C(CO)(=O)[O-].C(CO)(=O)[O-].C(CO)(=O)[O-] MIOUTPXNKVBIFR-UHFFFAOYSA-J 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940016157 solifenacin succinate 10 mg Drugs 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003890 succinate salts Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Definitions
- the present invention relates to an agent for improving urinary urgency, urinary frequency and urinary incontinence of neurogenic bladder, particularly urinary urgency and urinary frequency, comprising solifenacin or a salt thereof.
- Solifenacin has the following structure, and solifenacin or a salt thereof is a muscarinic M receptor.
- Patent Document 1 Non-Patent Document 1, Non-Patent Document 2, Non-Patent Document 3
- Its chemical name is (1S) -1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-power rubonic acid (3R) -quinutaridin-3-yl ester.
- Solifenacin or a salt thereof is useful for various diseases involving M receptors.
- Patent Document 1 It has been reported (Patent Document 1) and is effective for interstitial cystitis (Patent Document 2), relaxation of ciliary muscle tone (Patent Document 3), and irritable bowel syndrome (Non-Patent Document 4) Sex has also been reported. Solifenacin succinate, a succinate of solifenacin, is also an unstable bladder, a neurological disease that can cause detrusor overactivity, urinary tract infections and stones, history of lumbar radiation, and pelvic organs. Efficacy for urgency, frequent urination, and urinary incontinence has been confirmed in patient populations without tumors (Non-patent Document 5).
- Non-patent Document 6 a state in which urinary urgency, frequent urination, and urinary incontinence occur in the absence of a disease that can cause the disease is defined as overactive bladder (Non-patent Document 6).
- urinary urgency is “a sudden, uncontrollable urinary urgency and difficult to endure” That “Complaints” and frequent urination are “patient complaints of excessive urination”, and urinary incontinence is “patient complaints of urine leaking regardless of their will”.
- Patent Document 1 solifenacin or a salt thereof is used as a muscarinic M antagonist.
- a disease that may be effective as a prophylactic or therapeutic agent it may be used in neurogenic pollakiuria, neurogenic bladder, nocturnal enuresis, unstable bladder, bladder spasticity, chronic cystitis, etc.
- Urinary diseases such as urinary incontinence and frequent urination, chronic obstructive pulmonary disease, chronic bronchitis, respiratory diseases such as asthma and rhinitis, gastrointestinal diseases such as irritable bowel syndrome, spastic colitis and diverticulitis Yes.
- the effectiveness against neurogenic bladder is not disclosed with specific data.
- neurogenic bladder refers to abnormalities in bladder function in patients with neurological disorders such as cerebral infarction, multiple sclerosis, spinal cord injury, Parkinson's disease, and congenital abnormalities in the nervous system It refers to the state (Non-patent document 8, Non-patent document 9, Non-patent document 10). Therefore, neurogenic bladder with urinary urgency, frequent urination and urinary incontinence is clearly distinguished from unstable bladder with urinary urgency, frequent urination and urinary incontinence in the absence of causative diseases such as neurological disorders. The sensitivity to drugs is different (Non-patent document 10, Non-patent document 11).
- Non-patent Document 11 oxiputinin has been reported to have therapeutic effects on multiple sclerosis, spinal cord injury, urgency of urinary urinary bladder associated with Parkinson's disease, frequent urination, and urinary incontinence.
- the dose of oxiputinin required for this was higher than the dose required to treat the symptoms of urinary urgency, frequent urination and incontinence of the unstable bladder.
- Non-Patent Document 12 There are also reports that the efficacy of oxiputinin in patients with cerebrovascular disorders is unknown.
- Non-patent Document 12 Toltero in patient populations with a sense of urgency, frequent urination and urinary incontinence
- Toltero in patient populations with a sense of urgency, frequent urination and urinary incontinence In Jin's clinical trials, effectiveness against frequent urination and urinary incontinence has been confirmed, but it has been reported that the effectiveness against urinary urgency cannot be evaluated (Non-patent Document 13).
- tolterodine trial results in a population of patients with urinary or neurogenic bladders who have a sense of urgency, frequent urination, and urinary incontinence indicate their effectiveness in urinary frequency and urinary incontinence.
- the effectiveness of urgency is not described (Non-Patent Document 14).
- Tolterodine is effective for urinary incontinence in patients with neurogenic bladder who are unable to urinate, but higher doses may be required for the treatment of unstable bladder for best results. It has been suggested (Non-patent Document 15), and no effects on urinary urgency and frequent urination symptoms have been reported.
- solifenacin or a salt thereof is disclosed as a capsaicin-sensitive sensory nerve inhibitor, and dimethyl sulfoxide interstitial cystitis, which exhibits a capsaicin-sensitive sensory nerve suppression action in the US FDA, is disclosed. Since the use of the drug has been approved and put to practical use, sorifenacin or its salt may be effective as a disease that is likely to be hypersensitivity in the lower urinary tract, which is similar to interstitial cystitis, and Z Or nonbacterial prostatitis is mentioned. However, in the neurogenic bladder of solifenacin or its salts Neither description nor suggestion is effective.
- a report on the relationship between cabsaicin-sensitive sensory nerves and urinary urgency, frequent urination and urinary incontinence in neurogenic bladder includes C-fiber selective neurotoxins kabusaicin and regi-feratoxin with vanilloid receptor stimulation has been reported to be useful in improving urgency, frequent urination, and urinary incontinence in patients with multiple sclerosis or spinal cord injury (Non-Patent Document 16, Non-Patent Document 9). However, both capsaicin and regi-feratoxin are still being used in clinical trials and have not yet been put into clinical use. Also, for these uses, they are not administered orally.
- capsaicin and regi-feratoxin which are expected to be effective against urinary urgency, frequent urination, and urinary incontinence of overactive bladder, that is, unstable bladder, have been studied in human and interstitial bladder. It is limited to patients with inflammation (Non-Patent Document 9), and there is no literature reporting usefulness to unstable bladder. The reason for this is that these drugs are administered into the bladder from the urethra through force tails, and the administration method is not only invasive. This is probably due to systemic side effects that appear (Non-patent Document 9). Therefore, the doses of capsaicin and resi-ferratoxin required for the treatment of urinary urgency, frequent urination and urinary incontinence of unstable bladder are completely unknown. In fact, these drugs are not given orally.
- Non-Patent Document 2 Drugs of the Future, 1999, No. 24, No. 8, p.871-874
- Non-Patent Document 3 Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 366th
- Non-Patent Document 4 Japanese Journal of Pharmacology, 2001, 86th, No. 3, p.281-28 8
- Non-Patent Document 5 BJU International, 2004, No. 93, p.303-310
- Non-Patent Document 6 Drugs, 2004, No. 64, No. 15, p.1643-1656
- Non-Patent Document 7 Neurology and Urodynamics, 2002, 21st, p.167-178
- Non-patent Document 8 Revue du Praticien, 1995, 45th, p.331-335
- Non-Patent Document 9 The Journal of Urology, 1999, No. 162, p.3-11
- Non-Patent Document 10 Spinal Cord, 2004, No. 42, p.267-272
- Non-Patent Document ll The Journal of Urology, 2004, No.171, p.749-751
- Non-Patent Document 12 The Journal of Urology, 2001, 165, p.359-370
- Non-Patent Document 13 Neurology and Urodynamics, 1998, Vol. 17, p. 499-512
- Non-Patent Document 14 The Journal of Urology, 1999, Vol. 161, p. 1551-1555
- Non-Patent Document 15 Journal of Spinal Cord Medicine, 2004, Vol. 27, No. 3, p.214-21
- Non-Patent Document 16 The Journal of Urology, 2004, No.171, p.251-255
- Patent Document 1 European Patent No. 801067
- Patent Document 2 International Publication No. WO 2003/6019 Pamphlet
- Patent Document 3 Japanese Patent Application Publication No. 2002-104968
- the present inventors have conducted intensive studies on drugs that reduce urinary urgency, frequent urination, and urinary incontinence due to neurogenic bladder.
- overactive bladder that is, urinary urgency associated with unstable bladder
- Surifenacin succinate used as a treatment for urinary and urinary incontinence
- solifenacin succinate the free base solifenacin
- solifenacin succinate as a daily dose, (a) 5 mg to 10 mg of solifenacin succinate, or (b) 5 mg to 10 mg of solifenacin succinate and an equimolar amount of solifenacin
- An agent for improving urinary urgency, frequent urination, or urinary incontinence by a neurogenic bladder, comprising an pharmaceutically acceptable salt thereof as an active ingredient is provided; particularly for oral administration as described above
- An improving agent further provided is the above-described improving agent for use in adult patients.
- the above-mentioned medicament which is an agent for improving urgency due to neurogenic bladder is preferable; as another aspect, the above-mentioned medicament which is an agent for improving frequent urination due to neurogenic bladder is preferable; As an embodiment, an agent for improving urinary incontinence by neurogenic bladder is preferred.
- the daily dose is (a) 5 mg of solifenacin succinate, or (b) 5 mg of solifenacin succinate and an equimolar amount of solifenacin or a pharmaceutically acceptable salt thereof.
- the above-mentioned improving agent is preferably contained as an active ingredient; in another embodiment, the daily dose is (a) 10 mg of solifenacin succinate or (b) 10 mg of solifenacin succinate as an equimolar amount.
- the above improving agent containing solifenacin or a pharmaceutically acceptable salt thereof as an active ingredient is preferred.
- solifenacin succinate for the manufacture of an agent for improving urinary urgency, frequent urination, or urinary incontinence by neurogenic bladder
- B The use of 5 mg to 10 mg of solifenacin succinate and equimolar amounts of solifenacin or a pharmaceutically acceptable salt thereof as a daily dose is provided; in particular, improvers are improved for oral administration.
- improvers are improved for oral administration.
- the improver is an improver for use in an adult patient.
- the above-mentioned use in which the improving agent is an agent for improving urgency due to neurogenic bladder is preferable; in another aspect, the above-described use in which the improving agent is an agent for improving frequent urination due to neurogenic bladder is preferable.
- Another preferred embodiment is the use described above, wherein the ameliorating agent is an ameliorating agent for urinary incontinence by neurogenic bladder! /.
- the improver is (a) 5 mg of solifenacin succinate, or (b) 5 mg of solifenacin succinate and an equimolar amount of solifenacin or its pharmaceutical preparation.
- a pharmaceutically acceptable salt as a daily dose is preferred; in another embodiment, (a) 10 mg of solifenacin succinate, or (b) 10 mg of solifenacin succinate or equimolar amounts of solifenacin or The use of the pharmaceutically acceptable salt as a daily dose is preferred.
- solifenacin succinate as a daily dose, (a) 5 mg to 10 mg of solifenacin succinate, or (b) 5 mg to 10 mg of solifenacin succinate and an equimolar amount of solifenacin Young Or a method of improving urinary urgency, frequent urination, or urinary incontinence by a neurogenic bladder, comprising administering to a patient a pharmaceutically acceptable salt thereof; Improvement method; The above improvement method is further provided wherein the patient is an adult patient.
- the above-described improvement method of urgency due to neurogenic bladder is preferable; as another aspect, the above-described improvement method of frequent urination due to neurogenic bladder is preferable; and as another aspect, neurogenicity
- the above method of improving urinary incontinence by the bladder is preferred.
- the daily dose is (a) 5 mg of solifenacin succinate, or (b) 5 mg of solifenacin succinate and an equimolar amount of solifenacin or a pharmaceutically acceptable product thereof.
- the above-mentioned improvement method comprising administering a salt is preferable; in another embodiment, as a daily dose, (a) 10 mg of solifenacin succinate, or (b) 10 mg of solifenacin succinate, etc.
- the improved method described above comprising administering a molar amount of solifenacin or a pharmaceutically acceptable salt thereof is preferred.
- the agent for improving urinary urgency, frequent urination, or urinary incontinence by the neurogenic bladder provided by the present invention, the agent for improving urinary urgency, frequent urination, or urinary incontinence by the neurogenic bladder
- the cause of neurogenic bladder in the use for manufacturing and improvement of urinary urgency, frequent urination, or urinary incontinence due to neurogenic bladder is due to cerebrovascular disorder, cerebral infarction or trauma Brain and spinal cord injury, multiple sclerosis, Parkinson's disease, peripheral neuropathy, congenital dysplasia of the nervous system, various spinal lesions: fractures, cervical and lumbar spondylosis, deformed spondylosis, spine Spinal cord compression due to spinal cord stenosis, etc.
- urinary urgency due to neurogenic bladder caused by these diseases frequent urination Or urinary incontinence-improving agent
- the use for the production of urinary urgency, frequent urination, or urinary incontinence by neurogenic bladder, and urinary urgency, frequent urination, or urine due to neurogenic bladder caused by these diseases Methods for improving incontinence are provided.
- the medicament of the present invention is useful as an agent for improving urgency, frequent urination and urinary incontinence due to neurogenic bladder.
- antimuscarinic agents are used to treat these symptoms of neurogenic bladder.
- the medicament of the present invention treats these symptoms of neurogenic bladder with the treatment of unstable bladder presenting these symptoms It has a surprising effect in that the effect is clearly manifested at the same dose required for the drug.
- solifenacin succinate is currently used as a treatment for urgency, frequent urination and urinary incontinence in patients with unstable bladder, ie overactive bladder, at the same dose as neurogenic Can treat urinary urgency, frequent urination and incontinence in bladder patients.
- the medicament of the present invention is an agent for improving urinary urgency, frequent urination and urinary incontinence associated with neurogenic bladder which can be used safely and easily, especially for oral administration. It is an agent.
- Solifenacin which is an active ingredient of the medicament of the present invention, can be easily obtained by the method described in Patent Document 1, the method obvious to those skilled in the art, or a modification thereof.
- the "salt" in “solifenacin or a salt thereof” may be any acid addition salt of solifenacin and a pharmaceutically acceptable acid, specifically, hydrochloric acid, odor Acid addition salts with inorganic acids such as hydrofluoric acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid; formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, Examples include acid addition salts with organic acids such as lactic acid, malic acid, tartaric acid, citrate, methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, sparpagic acid, and glutamic acid.
- solifenacin succinate which is an acid addition salt with succinic acid.
- Solifenacin which is an active ingredient of the present invention, includes those isolated from these optical isomers and mixtures thereof, preferably (1S) -1-phenol-1,2,3,4 -Tetrahydroisoquinoline-2-carboxylic acid (3R) -quinutaridin-3-yl ester or (1R) -1-phenol-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R) -quinutaridin-3 -Yl ester, and (1S) -1-phenol-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R) -quinutaridin-3-yl ester is particularly preferable. Therefore, the most preferred The active ingredient of Ming's medicine is succinate of (1S) -1-phenol-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R) -quinut
- the active ingredients of the medicament of the present invention include solvates such as ethanol solvate and ethyl acetate solvate, hydrates, and crystal polymorphs.
- the medicament of the present invention can be prepared by a commonly used method using solifenacin or a salt thereof and a pharmaceutical carrier, excipient, or other additive that is usually used for formulation.
- sorifenacin or its salt power at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polybulurpyrrolidone, metasilicic acid. Mixed with magnesium aluminate.
- the composition contains additive additives other than inert diluents, for example, lubricants such as magnesium stearate, disintegrants such as calcium calcium glycolate, stabilizers, solubilizing agents and the like according to a conventional method. It may be. If necessary, tablets or pills may be coated with sugar coating such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, or a gastric or enteric film! /.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, commonly used inert diluents, Examples include purified water and ethanol.
- the composition may contain adjuvants such as wetting agents and suspending agents, sweeteners, flavors, fragrances and preservatives.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- aqueous solutions and suspensions include distilled water for injection and physiological saline.
- non-aqueous solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as EtOH, polysorbate 80, and the like.
- Such a composition may further contain auxiliary agents such as preservatives, wetting agents, emulsifying agents, dispersing agents, stabilizing agents and solubilizing agents. These include, for example, bacterial retention It is sterilized by filtration through a filter, blending of a disinfectant or irradiation. They can also be prepared by preparing a sterile solid composition and dissolving it in sterile water or a sterile solvent for injection before use.
- the medicament of the present invention can be used in combination with other drugs used for the treatment of urological diseases and neurological diseases simultaneously or with time.
- examples of drugs that can be used in combination with the drug of the present invention include tamsulosin, botulinum toxin, interferon, tiza-dinin, dalachilemer, repodopa, amantadine and the like.
- the medicament of the present invention is a force that can be appropriately taken into account depending on the symptoms, medical history, body weight, sex, age, etc. of the patient.
- Solifenacin succinate 5 mg to 10 mg as a daily dose, or solifenacin as a daily dose
- Its pharmaceutically acceptable salt is administered in an equimolar amount with 5-10 mg solifenacin succinate.
- the daily dose can be divided into 4 doses twice a day, but preferably once a day.
- administration is preferably by oral administration.
- the dose of cono, solifenacin succinate or solifenacin as a free base according to the pharmaceutical composition of the present invention is assumed to be administered to men and women over 18 years old. May be used at lower doses. Specifically, 1/2 mg of sorifenacin succinate can be administered as 2.5 mg to 5.0 mg or 1.9 mg to 3.8 mg of solifenacin as the free base.
- FIG. 1 is a graph showing changes in bladder capacity in a frequent urine model rat associated with neurogenic bladder produced by the method of Example 1.
- FIG. 2 is a graph showing changes in urination volume in a frequent urine model rat associated with neurogenic bladder produced by the method of Example 1.
- Cerebral ischemia was induced by incising the neck of the rat under halothane anesthesia, inserting a nylon thread into the common carotid artery internal carotid artery, and indwelling the tip to the origin of the middle cerebral artery. The next day, using the method of Garcia et al. (Stroke, 1995, pp. 26, pp. 672-634), observe and score neurological symptoms and identify animals with moderate or higher symptoms (scores of 13 or less). Selected.
- Urinary bladder tension-Yule is connected to a syringe pump via a three-way stopcock to induce continuous urination by injecting physiological saline into the bladder, and the other end of the three-way stopcock is connected to a pressure transducer to increase the bladder pressure. It was measured. After stabilizing the micturition reflex, the drug dose force tailor inserted into the external jugular vein was also administered the test drug.
- the amount of physiological saline injection necessary to cause a single micturition reflex at 30 minutes after drug administration that is, the bladder capacity, and the amount of urination per time were measured. The results are shown in average standard error.
- Student's t-test was used to compare the sham-operated group and the cerebral infarction group, and Dunnett's multiple comparison test was used to compare the drug-administered group and the non-administered group.
- solifenacin succinate increased bladder capacity and urination in a dose-dependent manner at doses of 0.03 mg / kg or higher.
- Propiverine hydrochloride increased urination volume at 0.3 mg / kg or higher, and bladder capacity at lmg / kg.
- solifenacin succinate increased the bladder capacity and urination volume in rat model of frequent urination due to neurogenic bladder as well as propiverine hydrochloride. This was considered to be effective as a remedy for frequent urination due to intrinsic bladder.
- Example 2 A study on human urinary urgency due to neurogenic bladder, frequent urination and urinary incontinence Efficacy of solifenacin succinate
- the causes of urgency, frequent urination and urinary incontinence include neurogenic bladder (cerebral infarction or brain damage due to cerebral contusion, peripheral neuropathy, and cervical or lumbar spondylosis, Cervical or lumbar spondylolisthesis, intervertebral disc herniation, based on spinal stenosis, etc., and unstable bladder (neuropathies that can cause detrusor overactivity, urinary tract infections) And calculus, radiation history of the lumbar region, and tumors of the pelvic cavity organs).
- the average number of urinations per 24-hour period is 8 or more, and the following conditions (1) and (2) Patients who meet at least one of the following.
- Group S5 Solifenacin succinate 5 mg (equivalent to 3.8 mg solifenacin converted to free base)
- Group S10 Solifenacin succinate 10 mg (equivalent to 7.5 mg solifenacin converted to free base)
- group S5 and group B showed similar effects, and group S10 showed good results. That is, in any of the drug administration groups, an improvement effect on the urinary urgency of the unstable bladder was observed. On the other hand, in patients with neurogenic bladder, an improvement effect on urgency was observed only in the group administered the medicament of the present invention, i.e., group S5 and group S10, but in group B, improvement in urgency was improved. No effect was seen.
- urinary incontinence was improved in patients with unstable bladder in any drug administration group.
- an improvement effect on urinary incontinence was observed in all drug administration groups.
- propiverine hydrochloride one of the antimuscarinic agents, improved urinary incontinence in patients with neurogenic bladder at a dose of 20 mg, which showed urinary urgency, frequent urination and urine associated with unstable bladder It was confirmed to be the same dose that improved incontinence. However, this dose has no effect on improving urgency and frequent urination in patients with neurogenic bladder, and in order to obtain these effects, urinary urgency, frequent urination and urine in unstable bladders are higher than 20 mg. It was suggested that higher doses were needed than needed to improve incontinence.
- pharmaceutical comprising the pharmaceutical in a 5 mg of Sorifuenashin succinate of the present invention, and a pharmaceutical containing 10 m g of Sorifuenashin succinate urinate switching Hasamakan in neurogenic bladder patients, urinary frequency and It was found to improve all symptoms of urinary incontinence.
- This dose is the same as the dose that improves urgency, frequent urination, and urinary incontinence in patients with unstable bladder, and 5 mg, which is the clinically recommended dose (the maximum clinically recommended dose of 10 mg), is neurological. It was found to be effective for endogenous bladder.
- antimuscarinic drugs generally require higher doses for treating urinary urgency, frequent urination and urinary incontinence in patients with neurogenic bladder than are necessary to treat these symptoms in patients with unstable bladder.
- the drug containing the solifenacin of the present invention is completely different from the effect of the antimuscarinic agent, and is used for the treatment of urinary urgency, frequent urination and urinary incontinence in patients with neurogenic bladder. It was revealed that the therapeutic effect can be obtained at the same dose as that required for the treatment of the symptoms.
- the medicament containing the solifenacin of the present invention since the medicament containing the solifenacin of the present invention exhibits completely different properties from those of the antimuscarinic agent, it not only acts as an antimuscarinic agent but also cooperates with some other action.
- Urinary urgency of neurogenic bladder patients at the same dose that achieves the improvement of symptoms in patients with unstable bladder in other words, a dose greater than the dose that achieves improvements in symptoms of unstable bladder patients It is considered that the improvement of frequent urination and incontinence was achieved.
- the drug containing solifenacin of the present invention is high enough to exceed the recommended dose for unstable bladder in treating urinary urgency, frequent urination and urinary incontinence in patients with neurogenic bladder. Not only does it need to be used in doses, it can reduce side effects and can be used clinically safely.
- the medicament of the present invention is a cerebrovascular disorder or cerebral infarction, brain or spinal cord injury due to trauma, multiple sclerosis, Parkinson's disease, congenital dysplasia of the nervous system, peripheral neuropathy, and various spinal inferences.
- Neurodegenerative diseases such as fractures, cervical / lumbar spondylosis, degenerative spondylosis, spondylolisthesis, spinal canal stenosis, spinal cord compression or damage based on disc herniation, etc. It is useful as an agent for improving urinary urgency, frequent urination and urinary incontinence of neurogenic bladder as a causative disease, particularly for oral administration.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2599158A CA2599158C (en) | 2005-02-25 | 2006-02-23 | Pharmaceutical agent comprising solifenacin |
EP06714366A EP1852117A4 (en) | 2005-02-25 | 2006-02-23 | PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN |
US11/817,097 US20090131469A1 (en) | 2005-02-25 | 2006-02-23 | Pharmaceutical agent comprising solifenacin |
JP2007504758A JPWO2006090759A1 (ja) | 2005-02-25 | 2006-02-23 | ソリフェナシン含有医薬 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-050370 | 2005-02-25 | ||
JP2005050370 | 2005-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006090759A1 true WO2006090759A1 (ja) | 2006-08-31 |
Family
ID=36927397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/303226 WO2006090759A1 (ja) | 2005-02-25 | 2006-02-23 | ソリフェナシン含有医薬 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090131469A1 (ja) |
EP (1) | EP1852117A4 (ja) |
JP (1) | JPWO2006090759A1 (ja) |
CA (1) | CA2599158C (ja) |
WO (1) | WO2006090759A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009013846A1 (ja) * | 2007-07-20 | 2009-01-29 | Astellas Pharma Inc. | 前立腺肥大に伴う下部尿路症状の改善用医薬組成物 |
WO2010090172A1 (ja) * | 2009-02-04 | 2010-08-12 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008128028A2 (en) * | 2007-04-11 | 2008-10-23 | Dr. Reddy's Laboratories Ltd. | Solifenacin compositions |
PL2216021T3 (pl) | 2007-11-02 | 2013-03-29 | Astellas Pharma Inc | Kompozycja farmaceutyczna do leczenia zespołu pęcherza nadreaktywnego |
EP2286810A4 (en) * | 2008-05-16 | 2011-07-20 | Axis Inc | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FIBROMYALGIA |
EP2181707A1 (en) * | 2008-11-04 | 2010-05-05 | Astellas Ireland Co., Ltd. | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent |
CN102743757A (zh) * | 2012-07-09 | 2012-10-24 | 张家华 | 治疗膀胱流出道梗阻所致膀胱活动过度的药物 |
EP4255398A1 (en) | 2020-12-01 | 2023-10-11 | Adamed Pharma S.A. | Orally-administered preparation containing solifenacin and tamsulosin |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996020194A1 (fr) * | 1994-12-28 | 1996-07-04 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives de quinuclidine et composition pharmaceutique les contenant |
JP2000109481A (ja) * | 1999-10-13 | 2000-04-18 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体含有医薬 |
JP2003267977A (ja) * | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
WO2003103659A1 (ja) * | 2002-06-07 | 2003-12-18 | 山之内製薬株式会社 | 過活動膀胱治療剤 |
WO2004047838A2 (de) * | 2002-11-27 | 2004-06-10 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzung aus beta-3-adrenozeptor-agonisten und antimuskarinika |
JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
WO2005092889A1 (ja) * | 2004-03-25 | 2005-10-06 | Astellas Pharma Inc. | ソリフェナシンまたはその塩の固形製剤用組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100874815B1 (ko) * | 2001-07-10 | 2008-12-19 | 아스텔라스세이야쿠 가부시키가이샤 | 간질성 방광염 치료용 의약 조성물 |
BR0307772A (pt) * | 2002-02-19 | 2004-12-07 | Pharmacia Corp | Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência |
-
2006
- 2006-02-23 US US11/817,097 patent/US20090131469A1/en not_active Abandoned
- 2006-02-23 EP EP06714366A patent/EP1852117A4/en not_active Withdrawn
- 2006-02-23 CA CA2599158A patent/CA2599158C/en not_active Expired - Fee Related
- 2006-02-23 WO PCT/JP2006/303226 patent/WO2006090759A1/ja active Application Filing
- 2006-02-23 JP JP2007504758A patent/JPWO2006090759A1/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996020194A1 (fr) * | 1994-12-28 | 1996-07-04 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives de quinuclidine et composition pharmaceutique les contenant |
JP2000109481A (ja) * | 1999-10-13 | 2000-04-18 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体含有医薬 |
JP2003267977A (ja) * | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
WO2003103659A1 (ja) * | 2002-06-07 | 2003-12-18 | 山之内製薬株式会社 | 過活動膀胱治療剤 |
WO2004047838A2 (de) * | 2002-11-27 | 2004-06-10 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzung aus beta-3-adrenozeptor-agonisten und antimuskarinika |
WO2005092889A1 (ja) * | 2004-03-25 | 2005-10-06 | Astellas Pharma Inc. | ソリフェナシンまたはその塩の固形製剤用組成物 |
JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
Non-Patent Citations (2)
Title |
---|
SATO S. ET AL.: "Boko Sentakuteki Muscarine Juyotai Kikoyaku Solifenacine no Kenkyu Kaihatsu. (Research and development of solifenacin a bladder selective muscarinic receptor antagonist)", MEDICAL SCIENCE DIGEST, vol. 30, no. 8, 2004, pages 348 - 351, XP003001569 * |
See also references of EP1852117A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009013846A1 (ja) * | 2007-07-20 | 2009-01-29 | Astellas Pharma Inc. | 前立腺肥大に伴う下部尿路症状の改善用医薬組成物 |
WO2010090172A1 (ja) * | 2009-02-04 | 2010-08-12 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP1852117A4 (en) | 2010-10-27 |
JPWO2006090759A1 (ja) | 2008-07-24 |
CA2599158C (en) | 2011-01-25 |
US20090131469A1 (en) | 2009-05-21 |
EP1852117A1 (en) | 2007-11-07 |
CA2599158A1 (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006090759A1 (ja) | ソリフェナシン含有医薬 | |
US20090105298A1 (en) | Pharmaceutical composition for therapy of interstitial cystitis | |
JP6441267B2 (ja) | 過活動膀胱を治療するためのβ−3アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニストの組み合わせ | |
JP5744947B2 (ja) | 流涎症の治療のためのアルファ−2受容体アゴニスト(クロニジン)と抗ムスカリン剤(オキシブチニン)との組み合わせ | |
EP2754440B1 (en) | Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis | |
EP1728508A1 (en) | Medicine for prevention or treatment of frequent urination or urinary incontinence | |
JP5908072B2 (ja) | 腹圧性尿失禁予防剤及び/又は治療剤 | |
JP5566521B1 (ja) | 膀胱・尿道協調不全改善剤 | |
US10980767B2 (en) | Estrogen receptor ligands, compositions and methods related thereto | |
AU2016301689B2 (en) | Ameliorating agent for detrusor hyperactivity with impaired contractility | |
EP2172201A1 (en) | Pharmaceutical composition for amelioration of lower urinary tract symptom associated with prostatomegaly | |
JP2014114213A (ja) | 神経性疾患の治療又は予防のための医薬組成物 | |
JP4808613B2 (ja) | 頻尿または尿失禁の予防または治療用医薬 | |
JPWO2005049087A1 (ja) | 慢性骨盤痛症候群治療剤 | |
EP4176873A1 (en) | Urinary symptom therapeutic agent | |
JP2007290970A (ja) | 腹圧性及び混合型尿失禁治療剤 | |
KR20090114371A (ko) | 다발성 경화증 치료제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007504758 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006714366 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11817097 Country of ref document: US Ref document number: 2599158 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2006714366 Country of ref document: EP |